Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Fishman

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Addictive Behaviors|May 26, 2012
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youthDiane Warden, Geetha A Subramaniam, Thomas Carmody, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Journal of Substance Abuse Treatment|August 9, 2021
Corrigendum to "Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse" [Journal of Substance Abuse Treatment 131 (2021) 108447]Miranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
JAMA Network Open|May 8, 2024
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical TrialMatisyahu Shulman, Miranda G Greiner, Hiwot M Tafessu, et al.
Contemporary Clinical Trials|January 21, 2015
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trialJoshua D Lee, Peter D Friedmann, Tamara Y Boney, et al.
Contemporary Clinical Trials|August 14, 2016
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationaleJoshua D Lee, Edward V Nunes, Patricia Novo Mpa, et al.
Contemporary Clinical Trials|March 17, 2023
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation studyMiranda G Greiner, Matisyahu Shulman, Onumara Opara, et al.
Journal of Substance Use and Addiction Treatment|November 19, 2023
Linkage facilitation services for opioid use disorder: Taxonomy of facilitation practitioners, goals, and activitiesAaron Hogue, Milan F Satcher, Tess K Drazdowski, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Addictive Behaviors|May 26, 2012
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youthDiane Warden, Geetha A Subramaniam, Thomas Carmody, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Journal of Substance Abuse Treatment|August 9, 2021
Corrigendum to "Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse" [Journal of Substance Abuse Treatment 131 (2021) 108447]Miranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
JAMA Network Open|May 8, 2024
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical TrialMatisyahu Shulman, Miranda G Greiner, Hiwot M Tafessu, et al.
Contemporary Clinical Trials|January 21, 2015
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trialJoshua D Lee, Peter D Friedmann, Tamara Y Boney, et al.
Contemporary Clinical Trials|August 14, 2016
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationaleJoshua D Lee, Edward V Nunes, Patricia Novo Mpa, et al.
Contemporary Clinical Trials|March 17, 2023
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation studyMiranda G Greiner, Matisyahu Shulman, Onumara Opara, et al.
Journal of Substance Use and Addiction Treatment|November 19, 2023
Linkage facilitation services for opioid use disorder: Taxonomy of facilitation practitioners, goals, and activitiesAaron Hogue, Milan F Satcher, Tess K Drazdowski, et al.
Pageof 8